Rhabdomyosarcoma in infants younger than 1 year: A report from the children's oncology group

Suman Malempati, David A. Rodeberg, Sarah S. Donaldson, Elizabeth R. Lyden, James R. Anderson, Douglas S. Hawkins, Carola A S Arndt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND: Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children. METHODS: The authors analyzed the characteristics, treatment administered, outcomes, and patterns of failure for infants aged <1 year with nonmetastatic RMS who received multimodal therapy on Intergroup Rhabdomyosarcoma Study (IRS) protocols IRS-IV, D9602, and D9803. RESULTS: Seventy-six infants with nonmetastatic RMS were treated on the 3 protocols from 1991 to 2005. Their median age was 7.4 months (range, 0.1-12 months). Tumor histology included embryonal (57%), alveolar (21%), and undifferentiated sarcoma/other (22%). A parameningeal primary tumor site was less common in this infant cohort (3%) than in all patients who were treated on IRS-IV (25%). The estimated 5-year failure-free survival and overall survival rates (95% confidence interval [CI]) were 57% (95% CI, 44%-67%) and 76% (95% CI, 65%-85%), respectively, for infants compared with 81% (95% CI, 79%-83%) and 87% (95% CI, 85%-89%), respectively, for children ages 1 to 9 years. Twenty-three of 32 infants with treatment failure had local recurrence/progression with distant failure (n = 3) or without distant failure (n = 20). The overall local failure rate was 30%. The median time to treatment failure was 13 months. The failure-free survival rate was worse for infants who had IRS Group III tumors and for those who received less than protocol-recommended radiation therapy. CONCLUSIONS: Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure. The authors concluded that concerns regarding morbidity in infants and reluctance to use aggressive local control measures may lead to higher rates of local failure.

Original languageEnglish (US)
Pages (from-to)3493-3501
Number of pages9
JournalCancer
Volume117
Issue number15
DOIs
StatePublished - Aug 1 2011

Fingerprint

Rhabdomyosarcoma
Confidence Intervals
Treatment Failure
Sarcoma
Survival Rate
Neoplasms
Histology
Radiotherapy
Morbidity
Recurrence
Survival

Keywords

  • infant
  • pediatric
  • radiotherapy
  • rhabdomyosarcoma
  • sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Malempati, S., Rodeberg, D. A., Donaldson, S. S., Lyden, E. R., Anderson, J. R., Hawkins, D. S., & Arndt, C. A. S. (2011). Rhabdomyosarcoma in infants younger than 1 year: A report from the children's oncology group. Cancer, 117(15), 3493-3501. https://doi.org/10.1002/cncr.25887

Rhabdomyosarcoma in infants younger than 1 year : A report from the children's oncology group. / Malempati, Suman; Rodeberg, David A.; Donaldson, Sarah S.; Lyden, Elizabeth R.; Anderson, James R.; Hawkins, Douglas S.; Arndt, Carola A S.

In: Cancer, Vol. 117, No. 15, 01.08.2011, p. 3493-3501.

Research output: Contribution to journalArticle

Malempati, S, Rodeberg, DA, Donaldson, SS, Lyden, ER, Anderson, JR, Hawkins, DS & Arndt, CAS 2011, 'Rhabdomyosarcoma in infants younger than 1 year: A report from the children's oncology group', Cancer, vol. 117, no. 15, pp. 3493-3501. https://doi.org/10.1002/cncr.25887
Malempati S, Rodeberg DA, Donaldson SS, Lyden ER, Anderson JR, Hawkins DS et al. Rhabdomyosarcoma in infants younger than 1 year: A report from the children's oncology group. Cancer. 2011 Aug 1;117(15):3493-3501. https://doi.org/10.1002/cncr.25887
Malempati, Suman ; Rodeberg, David A. ; Donaldson, Sarah S. ; Lyden, Elizabeth R. ; Anderson, James R. ; Hawkins, Douglas S. ; Arndt, Carola A S. / Rhabdomyosarcoma in infants younger than 1 year : A report from the children's oncology group. In: Cancer. 2011 ; Vol. 117, No. 15. pp. 3493-3501.
@article{a28e744989ce45589eff2d60a72a1920,
title = "Rhabdomyosarcoma in infants younger than 1 year: A report from the children's oncology group",
abstract = "BACKGROUND: Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children. METHODS: The authors analyzed the characteristics, treatment administered, outcomes, and patterns of failure for infants aged <1 year with nonmetastatic RMS who received multimodal therapy on Intergroup Rhabdomyosarcoma Study (IRS) protocols IRS-IV, D9602, and D9803. RESULTS: Seventy-six infants with nonmetastatic RMS were treated on the 3 protocols from 1991 to 2005. Their median age was 7.4 months (range, 0.1-12 months). Tumor histology included embryonal (57{\%}), alveolar (21{\%}), and undifferentiated sarcoma/other (22{\%}). A parameningeal primary tumor site was less common in this infant cohort (3{\%}) than in all patients who were treated on IRS-IV (25{\%}). The estimated 5-year failure-free survival and overall survival rates (95{\%} confidence interval [CI]) were 57{\%} (95{\%} CI, 44{\%}-67{\%}) and 76{\%} (95{\%} CI, 65{\%}-85{\%}), respectively, for infants compared with 81{\%} (95{\%} CI, 79{\%}-83{\%}) and 87{\%} (95{\%} CI, 85{\%}-89{\%}), respectively, for children ages 1 to 9 years. Twenty-three of 32 infants with treatment failure had local recurrence/progression with distant failure (n = 3) or without distant failure (n = 20). The overall local failure rate was 30{\%}. The median time to treatment failure was 13 months. The failure-free survival rate was worse for infants who had IRS Group III tumors and for those who received less than protocol-recommended radiation therapy. CONCLUSIONS: Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure. The authors concluded that concerns regarding morbidity in infants and reluctance to use aggressive local control measures may lead to higher rates of local failure.",
keywords = "infant, pediatric, radiotherapy, rhabdomyosarcoma, sarcoma",
author = "Suman Malempati and Rodeberg, {David A.} and Donaldson, {Sarah S.} and Lyden, {Elizabeth R.} and Anderson, {James R.} and Hawkins, {Douglas S.} and Arndt, {Carola A S}",
year = "2011",
month = "8",
day = "1",
doi = "10.1002/cncr.25887",
language = "English (US)",
volume = "117",
pages = "3493--3501",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - Rhabdomyosarcoma in infants younger than 1 year

T2 - A report from the children's oncology group

AU - Malempati, Suman

AU - Rodeberg, David A.

AU - Donaldson, Sarah S.

AU - Lyden, Elizabeth R.

AU - Anderson, James R.

AU - Hawkins, Douglas S.

AU - Arndt, Carola A S

PY - 2011/8/1

Y1 - 2011/8/1

N2 - BACKGROUND: Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children. METHODS: The authors analyzed the characteristics, treatment administered, outcomes, and patterns of failure for infants aged <1 year with nonmetastatic RMS who received multimodal therapy on Intergroup Rhabdomyosarcoma Study (IRS) protocols IRS-IV, D9602, and D9803. RESULTS: Seventy-six infants with nonmetastatic RMS were treated on the 3 protocols from 1991 to 2005. Their median age was 7.4 months (range, 0.1-12 months). Tumor histology included embryonal (57%), alveolar (21%), and undifferentiated sarcoma/other (22%). A parameningeal primary tumor site was less common in this infant cohort (3%) than in all patients who were treated on IRS-IV (25%). The estimated 5-year failure-free survival and overall survival rates (95% confidence interval [CI]) were 57% (95% CI, 44%-67%) and 76% (95% CI, 65%-85%), respectively, for infants compared with 81% (95% CI, 79%-83%) and 87% (95% CI, 85%-89%), respectively, for children ages 1 to 9 years. Twenty-three of 32 infants with treatment failure had local recurrence/progression with distant failure (n = 3) or without distant failure (n = 20). The overall local failure rate was 30%. The median time to treatment failure was 13 months. The failure-free survival rate was worse for infants who had IRS Group III tumors and for those who received less than protocol-recommended radiation therapy. CONCLUSIONS: Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure. The authors concluded that concerns regarding morbidity in infants and reluctance to use aggressive local control measures may lead to higher rates of local failure.

AB - BACKGROUND: Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children. METHODS: The authors analyzed the characteristics, treatment administered, outcomes, and patterns of failure for infants aged <1 year with nonmetastatic RMS who received multimodal therapy on Intergroup Rhabdomyosarcoma Study (IRS) protocols IRS-IV, D9602, and D9803. RESULTS: Seventy-six infants with nonmetastatic RMS were treated on the 3 protocols from 1991 to 2005. Their median age was 7.4 months (range, 0.1-12 months). Tumor histology included embryonal (57%), alveolar (21%), and undifferentiated sarcoma/other (22%). A parameningeal primary tumor site was less common in this infant cohort (3%) than in all patients who were treated on IRS-IV (25%). The estimated 5-year failure-free survival and overall survival rates (95% confidence interval [CI]) were 57% (95% CI, 44%-67%) and 76% (95% CI, 65%-85%), respectively, for infants compared with 81% (95% CI, 79%-83%) and 87% (95% CI, 85%-89%), respectively, for children ages 1 to 9 years. Twenty-three of 32 infants with treatment failure had local recurrence/progression with distant failure (n = 3) or without distant failure (n = 20). The overall local failure rate was 30%. The median time to treatment failure was 13 months. The failure-free survival rate was worse for infants who had IRS Group III tumors and for those who received less than protocol-recommended radiation therapy. CONCLUSIONS: Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure. The authors concluded that concerns regarding morbidity in infants and reluctance to use aggressive local control measures may lead to higher rates of local failure.

KW - infant

KW - pediatric

KW - radiotherapy

KW - rhabdomyosarcoma

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79960700062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960700062&partnerID=8YFLogxK

U2 - 10.1002/cncr.25887

DO - 10.1002/cncr.25887

M3 - Article

C2 - 21264837

AN - SCOPUS:79960700062

VL - 117

SP - 3493

EP - 3501

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 15

ER -